Login to Your Account



Cardio3 BioSciences Grosses $30M in Brussels, Paris IPO

By Cormac Sheridan
Staff Writer

Monday, July 8, 2013
financings_resized.jpg

Shares in Cardio3 Biosciences SA performed strongly on their first day of trading, following a July 4 initial public offering (IPO) on the NYSE Euronext exchanges in Brussels and Paris that raised €23 million (US$29.6 million).

The Mont-Saint-Guibert, Belgium-based stem cell therapy developer priced the offering at €16.65 per share, at the bottom of the indicative price range of €16.65 to €19 per share it set in advance of the book-building process.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription